Clinical outcome after radical metastasectomy in renal cell carcinoma: Results from a randomized phase 2 study

7140 POSTER A Randomized Phase 2 Study of Axitinib Dose Titration in Patients With Advanced Renal Cell Carcinoma (RCC): Preliminary Pharmacokinetic and Ambulatory Blood Pressure (BP) Monitoring Results

European Journal of Cancer ◽

10.1016/s0959-8049(11)72055-x ◽

2011 ◽

Vol 47 ◽

pp. S517

Author(s):

V. Grunwald ◽

M.N. Fishman ◽

T.E. Hutson ◽

A. Bair ◽

Y. Chen ◽

...

Keyword(s):

Blood Pressure ◽

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Ambulatory Blood Pressure ◽

Renal Cell ◽

Advanced Renal Cell Carcinoma ◽

Dose Titration ◽

Phase 2 ◽

Phase 2 Study ◽

A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma

Annals of Oncology ◽

10.1093/annonc/mdw676 ◽

2017 ◽

Vol 28 (4) ◽

pp. 804-808 ◽

Cited By ~ 17

Author(s):

E. Jonasch ◽

E. Hasanov ◽

P.G. Corn ◽

T. Moss ◽

K.R. Shaw ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Phase 2 ◽

Phase 2 Study ◽

Randomized phase 2 study to assess the safety and efficacy of CRLX101 in combination with bevacizumab in patients (pts.) with metastatic renal cell carcinoma (RCC) versus standard of care (SOC).

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.tps4579 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. TPS4579-TPS4579 ◽

Cited By ~ 1

Author(s):

Martin Henner Voss ◽

Andrea Coates ◽

Edward Graeme Garmey ◽

Naomi B. Haas ◽

Thomas Hutson ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Standard Of Care ◽

Phase 2 ◽

Safety And Efficacy ◽

Phase 2 Study ◽

A randomized phase 2 study of the thrombospondin-mimetic peptide ABT-510 in patients with previously untreated advanced renal cell carcinoma

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.4607 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 4607-4607 ◽

Cited By ~ 7

Author(s):

S. W. Ebbinghaus ◽

M. Hussain ◽

N. M. Tannir ◽

M. S. Gordon ◽

A. A. Desai ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Advanced Renal Cell Carcinoma ◽

Phase 2 ◽

Mimetic Peptide ◽

Phase 2 Study ◽

CANTATA: A randomized phase 2 study of CB-839 in combination with cabozantinib vs. placebo with cabozantinib in patients with advanced/metastatic renal cell carcinoma.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.tps4601 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. TPS4601-TPS4601 ◽

Cited By ~ 5

Author(s):

Nizar M. Tannir ◽

Robert J. Motzer ◽

Neeraj Agarwal ◽

Ping-Yu Liu ◽

Samuel H. Whiting ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Phase 2 ◽

Phase 2 Study ◽

Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial

European Urology ◽

10.1016/j.eururo.2021.01.003 ◽

2021 ◽

Author(s):

Thomas Powles ◽

Michael B. Atkins ◽

Bernard Escudier ◽

Robert J. Motzer ◽

Brian I. Rini ◽

...

Keyword(s):

Clinical Trial ◽

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Disease Progression ◽

Renal Cell ◽

Phase 2 ◽

Efficacy And Safety ◽

Phase 2 Clinical Trial ◽

A phase 2 study of investigational TORC1/2 inhibitor TAK-228 and TAK-228 plus investigational PI3Kα-selective inhibitor TAK-117 vs everolimus in adults with advanced or metastatic clear-cell renal cell carcinoma (ccRCC) that has progressed on VEGF-targeted therapy

Annals of Oncology ◽

10.1093/annonc/mdx371.079 ◽

2017 ◽

Vol 28 ◽

pp. v328 ◽

Cited By ~ 1

Author(s):

T.K. Choueiri ◽

C. Porta ◽

C. Suarez Rodriguez ◽

R. Alter ◽

P. Czaykowski ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Targeted Therapy ◽

Cell Carcinoma ◽

Renal Cell ◽

Clear Cell ◽

Selective Inhibitor ◽

Phase 2 ◽

Cell Renal Cell Carcinoma ◽

Phase 2 Study

Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma

Clinical Genitourinary Cancer ◽

10.1016/j.clgc.2016.02.007 ◽

2016 ◽

Vol 14 (4) ◽

pp. 304-313.e6 ◽

Cited By ~ 9

Author(s):

Kathleen M. Mahoney ◽

Susanna Jacobus ◽

Rupal S. Bhatt ◽

Jiaxi Song ◽

Ingrid Carvo ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Phase 2 ◽

Phase 2 Study

Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study

The Lancet Oncology ◽

10.1016/s1470-2045(19)30513-3 ◽

2019 ◽

Vol 20 (10) ◽

pp. 1386-1394 ◽

Cited By ~ 23

Author(s):

Moshe C Ornstein ◽

Sumanta K Pal ◽

Laura S Wood ◽

Jackie M Tomer ◽

Brian P Hobbs ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Checkpoint Inhibitors ◽

Phase 2 ◽

Phase 2 Study

5 Mechanism based targeted therapy for hereditary leiomyomatosis and renal cell cancer (HLRCC) and sporadic papillary renal cell carcinoma: interim results from a phase 2 study of bevacizumab and erlotinib

European Journal of Cancer ◽

10.1016/s0959-8049(14)70131-5 ◽

2014 ◽

Vol 50 ◽

pp. 8 ◽

Cited By ~ 20

Author(s):

R. Srinivasan ◽

D. Su ◽

L. Stamatakis ◽

M.M. Siddiqui ◽

E. Singer ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Targeted Therapy ◽

Cell Carcinoma ◽

Renal Cell Cancer ◽

Renal Cell ◽

Cell Cancer ◽

Papillary Renal Cell Carcinoma ◽

Phase 2 ◽

Phase 2 Study ◽

Hereditary Leiomyomatosis